Curriculum Vitae – Prof. Mauro Magnani
MAGNANI Prof. Mauro, Professore di Biochimica (BIO 10) Dipartimento di Scienze Biomolecolari Università degli Studi di Urbino "Carlo Bo" Via Saffi, 2 61029 Urbino, Italy Phone +39 0722 305211 Fax +39 0722 305324 mauro.magnani@uniurb.it Nato: 9 Aprile 1953, Italy Lingue: Italiano, Inglese Formazione: Università di Urbino, Italy, 1976 Posizione attuale: Professore Ordinario di Biochimica e Direttore Sezione di Biotecnologie, Università di Urbino, Italy Carriera Professionale: Laureato in Biologia, Università di Urbino, 1976; Visiting Researcher, Dept. Biochemistry, Univ. Birmingham, 1980; Visiting Prof. Dept. Biolgy, Haifa, Israel, 1983; Asst. Prof. Univ. Urbino, 1977-82; Assoc. Prof., 1982-1986; Full Prof. of Biochemistry 1986- present ; Esperienze di Governance: Membro del Consiglio di Amministrazione Università di Urbino; 1995-2001 Preside, Facoltà di Scienze, Università di Urbino; 1998-2005 Director Interuniversity Consortium for Biotechnology (CIB), dal Novembre 2006 membro della Giunta e Vice-Direttore; 2001-2009 Vice Rettore Università di Urbino. Dal Settembre 2011 membro del Consiglio di Amministrazione della “Stazione Zoologica Anthon Dorn” Napoli, nominato dal Ministro dell’Università e della Ricerca a seguito di valutazione comparativa. PROFESSIONAL MEMBERSHIPS: Biochemical Society; Ital. Biochem. Soc. (member of the board); Int. Ass. Biomed. Gerontol.; Int. Soc. For The Use of Resealed Erythrocytes (President 1991-1993); Red Cell Research Group; European Haematology Association; International Society for Antiviral Research; AAAS; American Society of Human Genetics; International Society for Antiviral Research; International Society for Nucleosides, Nucleotides and Nucleic Acids, etc. ENTERPRENERIAL ACTIVITIES e principali riconoscimenti: Co-fondatore di due start up companies: Diatheva S.r.L. fondata nel 2002 e attualmente condotta da 12 researchers (www.diatheva.com); EryDel S.p.A. fondata nel 2007 e attualmente condotta da 10 professionisti e finanziata da due VC founds (www.erydel.com); Incluso nell’Albo Professionale dei Biologi n. 017484. Technical Director nominato dall’ “Agenzia Italiana del Farmaco, AIFA” con n. AIDT-19/2005; Premio “Genomic Pioneers” by HUGO and Ocimum (2008), membro dell’ “Accademia Raffaello”, Paul Harris Fellow della Rotary Foundation. Incluso nella lista dei“Top Italian Scientists” REFEREE: Diversi Programmi dell’ E.U.; The International Science Foundation (U.S.A.); Czech Academy of Sciences; The Executive Agency for Higher Education, Research, Development and Innovation Funding of Romania; Deutsche Forschungsgemeinschaft (DFG) German Research
Foundation; Progetto Finalizzato “Biotecnologie” del C.N.R.; Membro del Progetto “Patologia clinica e terapia dell’infezione da HIV” del Ministro della Salute; progetti PRIN e FIRB del MIUR; Membro del Comitato Post Genoma (C.N.R); Membro del “Comitato Educazione, Formazione e Ricerca” Ministero Politiche Comunitarie; Membro del “Comitato Nazionale per la Biosicurezza e le Biotecnologie” Presidenza Consiglio dei Ministri; Incluso nell’ “Albo degli Esperti” del M.I.U.R. e EU Eureka projects; Programmi di Biotecnologie delle Regioni Piemonte, Sardegna, Emilia Romagna, Trentino PRINCIPALI TEMI DI RICERCA: Red blood cell as drug-delivery systems and as circulating bioreactors; Development and delivery of biologics; Drug efficacy, resistance and drug toxicity; Pharmacogenetic profiling; Modulation of NF-kB and gene expression by oligonucleotide decoy; Nanomaterials in drug delivery and imaging; Recombinant vaccine production; HIV-persistence and reservoirs PUBLICAZIONI: oltre 400 articoli publcati su riviste scientifiche internazionali con referee (per una lista completa vedi PubMed http://www.ncbi.nlm.nih.gov/pubmed?term=Magnani%20M); H index = 37 Co-editor di tre libri: “Red Blood Cell Aging”, Plenum Press, N.Y., 1991, pp. 383. “The Use of Resealed Erythrocytes as Carriers and Bioreactors”, Plenum Press, N.Y., 1992, pp. 361. “Erythrocyte Engineering for Drug Delivery and Targeting”, Landes Bioscience, 2002. BREVETTI E DOMANDE DI BREVETTO: Europen Patent EP 0517986B1 M. Magnani, L. Rossi “Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions” US Patent 5,753,221 M. Magnani, L. Rossi “Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions” US Patent 6,139,836 Mauro Magnani, Ivo Panzani, Leonardo Bigi, Andrea Zanella “Method of encapsulating biologically active agents within erythrocytes, and apparatus therefor”. Assignee: Dideco S.p.A., Mirandola, Italy European Patent N. EP98830479.6 M. Magnani, G. Brandi, A. Fraternale, A. Casabianca “Pharmaceutical composition or compositionpackage containing a pyrimidine nucleoside analogue and a purine nucleoside analogue”. Brevetto C.N.R. N. RM92 A 000377 M. Magnani “Antigeni legati alla superficie esterna di eritrociti e procedimento per la loro preparazione” Brevetto C.N.R. N. RM 93 A 000474 M. Magnani “Eritrociti incorporanti alcool ossidasi e loro uso nelle intossicazioni da metanolo” Brevetto C.N.R. M. Magnani, L. Rossi, G. Brandi, E. Millo, G. Damonte, U. Benatti, A. De Flora “Profarmaco di acyclovir e suo uso in composizioni farmaceutiche” Brevetto di Invenzione N. MI2002A01196 – 06/06/1996 – PCT/IT 02/00368 del 13/06/2002 ; US Patent n. 7,645,788 B2 M. Magnani, C. Fiorucci, P. Filippone, G. Brandi, M. Paiardini. “Derivato tetramerico dell’indol-3 carbinolo ad attività anticancerogena e metodo di sintesi del derivato stesso”. Brevetto di Invenzione N. TO2001A01077 – 16/11/2001 M. Magnani, F. Graziano, A. Ruzzo “Mutazioni della linea germinale nel promotore del gene della E-caderina e metodi di diagnosi per individuare una maggiore suscettibilità al carcinoma gastrico”. Brevetto di Invenzione N.PCT/EP2004/05726 del 29/12/2004 U. Benfatti, G. Brandi, E. Garaci, M. Magnani, E. Millo, AT. Palamara, L. Rossi “Derivati del Glutatione e loro utilizzi per il trattamento delle malattie virali” United Kingdom – Patent Application N. 0613183.3; US 2010/0061937 A1; EP 07765215.4 M. Magnani, A. Antonelli . “Delivery of contrasting agents for magnetic resonance imaging” International Patent Application PCT/EP2010/003783 M. Magnani, L. Rossi, S. Biagiotti and M. Bianchi “Drug Delivery Systems” . REVIEWER: Nature Biotechnology; Biotechnology Advances; Trends in Biotechnology; Drugs; Leukemia; European Journal Haematology; Biotechnology and Applied Biochemistry; Biochimica et Biophysica Acta; Blood; Journal of Cellular Engineering; Journal of Internal Medicine; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; Mechanisms of Ageing and Development; Antiviral Research; Journal of Chromatography; Journal of Biological Regulators and Homeostatic Agents; Life Sciences; Biochemistry; International Journal of Biochemistry and Cell Biology; Human Gene Therapy; European Journal of Biochemistry; Clinical Pharmacokinetics; Autoimmunity; Oncogene; Analytical Biochemistry; The Hematology Journal; Talanta, Sports Medicine, Cell Biology and Toxicology; Letters in Applied Microbiology; Haematologica; J. Controlled Release; Gene; Nanomedicine; Harmful Algae; Analytica Chimica Acta, AIDS Research and Treatment, etc. Editorial Board: Current Drug Targets; The Open Pharmacology Journal; Biotechnology; World Journal of Pharmacology
Selezione delle pubblicazioni più recenti (solo 2011): 1. Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M.
J Clin Oncol. 2011 Oct 31. [Epub ahead of print] PMID:22042954 IF=18.970
2. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. Fraternale A, Paoletti MF, Dominici S, Buondelmonte C, Caputo A, Castaldello A, Tripiciano A, Cafaro A, Palamara AT, Sgarbanti R, Garaci E, Ensoli B, Magnani M.
Vaccine. 2011 Sep 16;29(40):6823-9. Epub 2011 Aug 2. PMID: 21816192 IF= 3.572
3. Binding force measurement of NF-κB-ODNs interaction: an AFM based decoy and drug testing tool. Menotta M, Crinelli R, Carloni E, Mussi V, Valbusa U, Magnani M.
Biosens Bioelectron. 2011 Oct 15;28(1):158-65. Epub 2011 Jul 18. PMID: 21802937 IF=5.361
4. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. De Santi M, Galluzzi L, Lucarini S, Paoletti MF, Fraternale A, Duranti A, De Marco C, Fanelli M, Zaffaroni N, Brandi G, Magnani M.
Breast Cancer Res. 2011 Mar 24;13(2):R33. [Epub ahead of print] PMID: 21435243 IF=5.785
5. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, Magnani M, Graziano F.
Ann Oncol. 2011 Jan;22(1):234-5. Epub 2010 Oct 6. PMID: 20926546 IF=6.452
6. Dexamethasone restrains ongoing expression of interleukin-23p19 in peripheral blood-derived human macrophages. Palma L, Sfara C, Antonelli A, Magnani M.
BMC Pharmacol. 2011 Jul 26;11:8. PMID:21791059
7. Glucocorticoid resistance in Crohn's disease and ulcerative colitis: an association study investigating GR and FKBP5 gene polymorphisms. Maltese P, Palma L, Sfara C, deRocco P, Latiano A, Palmieri O, Corritore G, AnneseV, Magnani M.
Pharmacogenomics J. 2011 Jul 26. doi: 10.1038/tpj.2011.26
8. Application of the standard addition method for the absolute quantification of neutral lipids in microalgae using Nile red. Bertozzini E, Galluzzi L, Penna A, Magnani M.
J Microbiol Methods. 2011 Oct;87(1):17-23. Epub 2011 Jul 13. PMID:21767582
9. Drug delivery by red blood cells. Biagiotti S, Paoletti MF, Fraternale A, Rossi L, Magnani M.
IUBMB Life. 2011 Aug;63(8):621-31. doi: 10.1002/iub.478
10. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F.
BMC Cancer. 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247. PMID:21669012
11. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G, Conaldi PG, Magnani M.
J Control Release. 2011 Sep 25;154(3):306-13. Epub 2011 May 27. PMID: 21640771
12. Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents. Antonelli A, Sfara C, Manuali E, Bruce IJ, Magnani M.
Nanomedicine (Lond). 2011 Feb;6(2):211-23. PMID:21385124
13. Redox regulation of the influenza hemagglutinin maturation process: a new cell-mediated strategy for anti-influenza therapy. Sgarbanti R, Nencioni L, Amatore D, Coluccio P, Fraternale A, Sale P, Mammola CL, Carpino G, Gaudio E, Magnani M, Ciriolo MR, Garaci E, Palamara AT.
Antioxid Redox Signal. 2011 Aug 1;15(3):593-606. PMID:21366409
14. Development of an oligonucleotide microarray for the detection and monitoring of marine dinoflagellates. Galluzzi L, Cegna A, Casabianca S, Penna A, Saunders N, Magnani M.
J Microbiol Methods. 2011 Feb;84(2):234-42. PMID:21138747
15. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
Crit Rev Oncol Hematol. 2011 Jun;78(3):243-51.PMID:20619672
Producing antiretroviral drugs in plants In 1983 Luc Montagnier who worked at the Pasteur Institute in France discovered that the acquired immune deficiency syndrome (AIDS) is caused by a retrovirus that is nowadays known as the human immunodeficiency virus (HIV). According to estimates of the Joint United Nations Program on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) 25 million
FDA NEWS RELEASE For Immediate Release: July 17, 2012 FDA Approves Weight-Management Drug Qsymia The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or ad